Health Care·Life Sciences Tools & Services·$4.4B
Stevanato Group S P (STVN) operates in the health care sector, specifically within life sciences tools and services. The company is known for its innovative solutions in drug delivery and packaging, which are crucial for the pharmaceutical industry, especially as demand for advanced medical solutions continues to grow.
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue Growth
Understanding revenue trends helps gauge demand for Stevanato's products in the competitive health care market.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
+0.88%
Avg Stock Reaction
+2.34%
In Q4-2025, Stevanato reported an EPS of $0.20, matching expectations, and saw a significant stock increase of 18.81% the following day. This performance suggests a stable financial position despite the lack of revenue data.
Management Promises & Guidance
Investors are cautiously optimistic about Stevanato's upcoming earnings report, especially given the company's recent performance. However, the lack of detailed analyst estimates leaves room for uncertainty.
Bull Case
If Stevanato exceeds EPS expectations and demonstrates strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.
Bear Case
Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could raise concerns about its market position and growth prospects.
EPS
N/AEarnings per share is a key indicator of the company's profitability and financial health.
Revenue Growth
N/AUnderstanding revenue trends helps gauge demand for Stevanato's products in the competitive health care market.
Gross Margin
N/AGross margin reflects the efficiency of production and pricing strategies, which are critical for maintaining profitability.
The print will turn on these two things.
Q1
What is the expected EPS for this quarter?
The EPS figure will be crucial in assessing the company's profitability and could significantly influence investor sentiment.
Q2
How is Stevanato addressing market competition and demand for its products?
Understanding the company's strategy in a competitive landscape will help investors gauge its future growth potential.
Why consensus could be wrong
The Street may underestimate Stevanato's ability to innovate and capture market share in the growing health care sector, especially given recent trends in drug delivery systems.
Supporting Evidence
The company's historical performance shows a consistent ability to surprise on the upside, with a 50% beat rate.
Recent trends in the pharmaceutical industry indicate increasing demand for advanced drug delivery solutions, which Stevanato specializes in.
Key Risk
If the EPS comes in below $0.18, it could undermine confidence in the company's growth trajectory.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will reflect the company's ability to navigate a competitive market and maintain profitability.
Bull Confirmed If
An EPS of $0.22 or higher would confirm strong operational performance and growth prospects.
Bear Confirmed If
An EPS below $0.18 could indicate challenges in meeting market expectations and growth.
Implied Move
±N/A
There is no available options market data to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Stevanato beats expectations, history suggests the stock could rise by around 10.76%, confirming strong demand and operational efficiency.
In-Line / Cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
If the company misses earnings expectations, history suggests a potential drop of around 4.77%, raising concerns about its market position.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026